Erste Group upgrades Johnson & Johnson stock rating to Buy from Hold

Published 23/07/2025, 14:14
Erste Group upgrades Johnson & Johnson stock rating to Buy from Hold

Investing.com - Erste Group upgraded Johnson & Johnson (NYSE:JNJ) stock rating from Hold to Buy on Wednesday.

The research firm cited Johnson & Johnson’s higher operating margin and return on equity compared to competitors as key factors in the upgrade decision.

Erste Group noted that Johnson & Johnson recently raised its outlook for both sales and earnings growth, with earnings per share expected to increase by nearly 9% year-over-year in 2025.

The firm considers Johnson & Johnson stock attractively valued based on its price-to-earnings ratio.

Erste Group expects Johnson & Johnson’s stock price to rise further in the medium term, driven by the company’s improved growth prospects.

In other recent news, Johnson & Johnson has received approval from the European Commission for its Darzalex subcutaneous formulation as a monotherapy for adults with high-risk smoldering multiple myeloma. This approval marks the first treatment available for this patient group, addressing a significant unmet clinical need. Additionally, the company has submitted a New Drug Application to the U.S. Food and Drug Administration for icotrokinra, an oral peptide aimed at treating moderate to severe plaque psoriasis in patients aged 12 and older. This submission is backed by data from four Phase 3 clinical trials showing positive results for skin clearance.

In terms of financial evaluations, RBC Capital has raised its price target for Johnson & Johnson to $185 from $181, maintaining an Outperform rating. This adjustment follows the company’s second-quarter performance, which surpassed expectations for both sales and earnings per share. UBS also increased its price target to $190 from $180, citing strong fundamentals and robust sales growth in the company’s innovative medicines portfolio. Meanwhile, Guggenheim adjusted its price target to $167 from $164, maintaining a Neutral rating. These developments reflect a positive outlook from analysts on Johnson & Johnson’s recent performance and future potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.